Abstract
Background Several studies assessed the effect of pre-morbid exposure to proton pump inhibitors (PPIs) on disease course in adult COVID-19 patients with somewhat inconsistent results.
Methods This population-based matched cohort study embraced first COVID-19 episodes in adults diagnosed up to August 15 2021 in Croatia. Considering over-the-counter (OTC) availability of PPIs, patients were classified based on exposure to PPIs and burden of PPI-requiring conditions as “non-users” (no issued prescriptions, no recorded treatment-requiring conditions between January 1 2019 and COVID-19 diagnosis), “possible users” (no issued prescriptions, recorded treatment-requiring conditions; OTC use possible) and “users” (different intensity of issued prescriptions over 12 months prior to diagnosis, at least one within 3 months). Subsets were mutually exactly matched in respect to a range of pre-COVID-19 characteristics. The contrast between “users” and “possible users” was considered the most informative for the effect of PPIs that is separate of the effect of PPI-requiring conditions.
Results Among 433609 COVID-19 patients, 332389 were PPI “non-users”, 18170 were “possible users”, and 55098 were “users”. Users and possible users were matched 41195 to 17334 and 33272 to 16434 in the primary and sensitivity analyses. There was no relevant difference between “users” and “possible users” regarding COVID-19-related mortality [RR=0.93 (95%CI 0.85-1.02; RD= -0.34% (−0.73, 0.03) in primary and RR=0.88 (0.78-0.98); RD=-0.45 (− 0.80, -0.11) in sensitivity analysis] or COVID-19-related hospitalizations [RR=1.04 (0.97-1.13); RD=0.29% (−0.16, 0.73) in primary and RR=1.05 (0.97-1.15); RD=0.32% (−0.12, 0.75) in sensitivity analysis].
Conclusions Pre-morbid exposure to PPIs does not affect the risk of death or hospitalization in adult COVID-19 patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Study was funded by the University of Zagreb School of Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is an observational study that used anonymized administrative data standardly collected on routine procedures, hence ethical approval was waived by the Ethics Committee of the Zagreb University School of Medicine and Croatian Institute for Public Health.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data can be obtained upon a reasonable request directly from the Croatian institute for public health.
